ARTICLE | Financial News
Gilead maintains guidance as HCV sales shrink
November 1, 2016 11:22 PM UTC
In its 3Q16 earnings statement, Gilead Sciences Inc. (NASDAQ:GILD) reported continued flagging sales for HCV treatments Harvoni ledipasvir/sofosbuvir and Sovaldi sofosbuvir. It said the decline in HCV sales was partially offset by increased sales in HIV products.
Gilead reported $7.41 billion in total 3Q16 revenue, down 10% from $8.21 billion in 3Q15 and shy of the $7.45 billion consensus. The company reiterated its previous guidance of $29.5-$30.5 billion in 2016 sales. It had lowered guidance in July in response to slowing sales and deeper discounts for Harvoni (see BioCentury Extra, July 25)...
BCIQ Company Profiles